GO:0010989 negative regulation of low-density lipoprotein particle clearance: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010989 describes any process that decreases the rate, frequency or extent of low-density lipoprotein (LDL) particle clearance from the blood via receptor-mediated endocytosis and degradation.
• PCSK9 is the best-characterized negative regulator of LDL clearance: it binds the LDL receptor (LDLR) and promotes its lysosomal degradation, reducing hepatic LDL uptake.
• Genetic variants in PCSK9, LDLR and related genes alter plasma LDL-cholesterol and cardiovascular risk, making this GO term central to dyslipidemia and atherosclerosis research.
• Beyond PCSK9, proteins such as SURF4 and LPA modulate lipoprotein trafficking and uptake, expanding the set of genes that can negatively regulate LDL clearance.
• Dietary trans fatty acids can raise LDL cholesterol through mechanisms consistent with reduced LDL clearance, linking nutrition to this regulatory process.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to causally test whether candidate genes negatively regulate LDL particle clearance.
Description
GO:0010989, negative regulation of low-density lipoprotein particle clearance, is a biological process that reduces the removal of low-density lipoprotein (LDL) particles from the blood. LDL clearance itself is defined as the receptor-mediated endocytosis of LDL particles and degradation of their constituent parts, and any process that decreases the rate, frequency or extent of this clearance falls under GO:0010989. Because plasma LDL-cholesterol is a major driver of atherosclerotic cardiovascular disease, understanding the molecular brakes on LDL clearance is a high-priority research area.
negative regulation of low-density lipoprotein particle clearance At A Glance
| GO ID | GO:0010989 |
|---|---|
| GO term | negative regulation of low-density lipoprotein particle clearance |
| Ontology | biological_process |
| Synonym | none |
| Major function | Decreases the rate, frequency or extent of LDL particle clearance via receptor-mediated endocytosis and degradation |
| Related process | Low-density lipoprotein particle clearance (GO:0034383) |
| Key regulator | PCSK9 promotes LDLR degradation and reduces LDL clearance |
| Disease relevance | Dyslipidemia, atherosclerosis, cardiovascular disease |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, lipid profiling, receptor binding assays |
What Is GO:0010989?
In practical terms, GO:0010989 covers any cellular or systemic mechanism that slows down or reduces the removal of LDL particles from circulation. This includes processes that decrease LDL receptor availability, impair receptor-mediated endocytosis, or otherwise lower the rate at which LDL is taken up and degraded by cells such as hepatocytes.
Why Is negative regulation of low-density lipoprotein particle clearance Important in Cell Biology?
GO:0010989 is important because it directly influences plasma LDL-cholesterol levels, a causal risk factor for atherosclerosis and coronary artery disease. PCSK9 is the prototypical negative regulator of LDL clearance, and its inhibition is a validated therapeutic strategy for lowering LDL cholesterol. Understanding additional negative regulators could reveal new drug targets and explain inter-individual variability in lipid levels and cardiovascular risk.
• PCSK9-mediated LDLR degradation is a major mechanism reducing LDL clearance and raising plasma LDL-C.
• Genetic variants in PCSK9 and LDLR are associated with altered serum lipid levels and cardiovascular outcomes.
• Negative regulation of LDL clearance contributes to dyslipidemia and atherosclerosis pathogenesis.
• Therapeutic inhibition of PCSK9 lowers LDL cholesterol by restoring LDL clearance.
• Dietary factors such as trans fatty acids may raise LDL-C partly by affecting LDL clearance pathways.
• SURF4 inactivation reduces plasma cholesterol, implicating trafficking proteins in LDL regulation.
• Lp(a) uptake pathways intersect with LDL clearance mechanisms and can be interrogated by CRISPR screening.
• Modeling this process helps evaluate drug candidates targeting LDL metabolism.
• CRISPR-based functional genomics can identify novel negative regulators of LDL clearance.
• Understanding this process supports precision medicine approaches to cardiovascular risk.
What Happens During negative regulation of low-density lipoprotein particle clearance?
PCSK9 binding to LDLR
In simple terms: PCSK9 acts like a lock that prevents the LDL receptor from being recycled.
PCSK9 is secreted and binds the extracellular EGF-A domain of the LDL receptor (LDLR). This binding is the initiating step in a major negative regulatory pathway for LDL clearance.
LDLR degradation
In simple terms: Instead of returning to the cell surface, the receptor is sent to the lysosome for destruction.
After binding, the PCSK9-LDLR complex is internalized and routed to lysosomes, where LDLR is degraded rather than recycled. This reduces the number of receptors available to clear LDL from the blood.
Reduced hepatic LDL uptake
In simple terms: With fewer receptors, the liver takes up less LDL, so LDL stays in the blood longer.
Because hepatocytes are the primary site of LDL clearance, PCSK9-mediated LDLR degradation decreases hepatic LDL uptake and increases plasma LDL-cholesterol.
Genetic and dietary modulation
In simple terms: Genes and diet can dial the strength of this brake up or down.
Variants in PCSK9 and other genes influence the efficiency of LDL clearance, and dietary trans fatty acids have been evaluated for their mode of action in raising LDL cholesterol, consistent with effects on clearance pathways.
Alternative lipoprotein trafficking pathways
In simple terms: Other proteins can also interfere with how lipoproteins are handled.
Proteins such as SURF4 and LPA-related pathways can influence lipoprotein secretion and uptake, providing additional nodes that may negatively regulate LDL particle clearance.
Key Genes Involved in GO:0010989 negative regulation of low-density lipoprotein particle clearance
The following genes and proteins have been experimentally linked to the regulation of LDL particle clearance or closely related lipoprotein metabolic pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PCSK9 | Binds LDLR and promotes its lysosomal degradation, reducing LDL clearance | Primary negative regulator; drug target for LDL lowering |
| LDLR | Mediates receptor-mediated endocytosis of LDL particles | Central to LDL clearance; mutations cause familial hypercholesterolemia |
| APOB | Structural apolipoprotein of LDL particles; ligand for LDLR | Required for LDL particle formation and clearance |
| APOA1 | Major HDL apolipoprotein; charge and conformation affect lipoprotein clearance | Model for how apolipoprotein properties regulate clearance |
| SURF4 | Endoplasmic reticulum cargo receptor involved in lipoprotein secretion | Hepatic inactivation reduces plasma cholesterol |
| LPA | Encodes apolipoprotein(a), a component of Lp(a) | Lp(a) uptake pathways intersect with LDL clearance |
| SORT1 | Sortilin, involved in lipoprotein trafficking and hepatic VLDL secretion | Modulates plasma lipid levels |
| MTTP | Microsomal triglyceride transfer protein; required for apoB lipoprotein assembly | Loss reduces LDL production and clearance substrate |
| ANGPTL3 | Inhibits lipoprotein lipase and endothelial lipase | Therapeutic target for lipid lowering |
| APOC3 | Inhibits lipoprotein lipase and hepatic remnant uptake | Associated with triglyceride-rich lipoprotein metabolism |
| IDOL | E3 ubiquitin ligase that promotes LDLR degradation | Alternative negative regulator of LDLR |
| MYLIP | Gene encoding IDOL | Modulates LDLR protein levels |
| HNF1A | Transcription factor regulating LDLR and other lipid genes | Mutations cause MODY and dyslipidemia |
| SREBF2 | Master transcription factor for cholesterol homeostasis and LDLR expression | Controls LDLR gene expression |
| NPC1L1 | Mediates intestinal cholesterol absorption | Target of ezetimibe; affects cholesterol balance |
| ABCG5 | Heterodimer with ABCG8; promotes sterol efflux | Mutations cause sitosterolemia |
| ABCG8 | Heterodimer with ABCG5; promotes sterol efflux | Mutations cause sitosterolemia |
| CETP | Cholesteryl ester transfer protein; transfers lipids between lipoproteins | Modulates HDL and LDL levels |
How Is negative regulation of low-density lipoprotein particle clearance Regulated?
The negative regulation of LDL particle clearance is itself regulated at multiple levels. PCSK9 expression is controlled by SREBP-2 and HNF1A, linking intracellular cholesterol status to LDLR degradation. IDOL (MYLIP) provides an additional ubiquitin-dependent route for LDLR degradation. Genetic variation in PCSK9, LDLR and related genes modulates the strength of this negative regulation and influences plasma LDL-cholesterol and cardiovascular risk. Dietary factors such as trans fatty acids have been evaluated for their mode of action in raising LDL cholesterol, with effects potentially involving altered clearance.
negative regulation of low-density lipoprotein particle clearance and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PCSK9 | Hypercholesterolemia, cardiovascular disease | Knockout and point-mutation HepG2 or mouse models |
| LDLR | Familial hypercholesterolemia | Knockout and knock-in hepatocyte models |
| APOB | Familial hypercholesterolemia, dyslipidemia | Knockout and overexpression cell models |
| SURF4 | Plasma cholesterol regulation | Liver-specific knockout mouse |
| LPA | Lipoprotein(a) metabolism | CRISPR screening in hepatocyte-like cells |
Atherosclerotic cardiovascular disease
Negative regulation of LDL clearance raises plasma LDL-cholesterol, a causal driver of atherosclerosis. PCSK9 gain-of-function variants increase LDL-C and cardiovascular risk, whereas loss-of-function variants lower both.
Familial hypercholesterolemia
Mutations in LDLR, APOB or PCSK9 cause familial hypercholesterolemia, a severe disorder characterized by impaired LDL clearance and premature cardiovascular disease.
Obesity and dyslipidemia
Genetic association studies have linked obesity-related loci to serum lipid levels, highlighting shared pathways that may include altered LDL clearance.
Lipoprotein(a) metabolism
Genome-scale CRISPR screening has been used to interrogate cellular Lp(a) uptake, revealing pathways that intersect with LDL clearance mechanisms.
From negative regulation of low-density lipoprotein particle clearance-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene reduce LDL clearance? | CRISPR knockout in HepG2 or primary hepatocytes |
| Does a specific variant alter PCSK9 function? | Point-mutation knock-in in cell lines |
| Can a therapeutic allele restore LDLR recycling? | Knock-in of variant cDNA |
| Does overexpression of a gene reduce LDL uptake? | Overexpression in hepatocyte cell lines |
| Which genes regulate Lp(a) or LDL uptake? | Genome-scale CRISPR library screening |
| Does SURF4 loss affect plasma cholesterol? | Liver-specific knockout mouse |
How to Study the negative regulation of low-density lipoprotein particle clearance Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on LDL uptake | Identify negative regulators |
| Point-mutation knock-in | Effect of specific variants | Model human dyslipidemia variants |
| Overexpression | Gain-of-function effects | Test candidate negative regulators |
| Lipid profiling | Plasma LDL-C and lipoprotein levels | Assess impact on clearance |
| Flow cytometry | Cell-surface LDLR levels | Measure receptor availability |
| Immunoblotting | LDLR and PCSK9 protein levels | Assess degradation |
| Fluorescent LDL uptake | Functional LDL internalization | Quantify clearance activity |
CRISPR knockout and point-mutation models
CRISPR-Cas9 knockout of candidate genes such as PCSK9 or LDLR in hepatocyte cell lines allows direct testing of their role in LDL clearance. Point mutations can model human variants associated with dyslipidemia.
Genome-scale CRISPR screening
Pooled CRISPR screens enable unbiased discovery of genes that negatively regulate lipoprotein uptake, as demonstrated for Lp(a) uptake pathways.
Lipid and lipoprotein profiling
Measuring plasma LDL-cholesterol, apoB and lipoprotein fractions in cell or animal models quantifies the functional impact of genetic perturbations on LDL clearance.
Receptor binding and degradation assays
LDLR surface expression, PCSK9 binding and lysosomal degradation can be assessed by flow cytometry, immunoblotting and fluorescent LDL uptake assays.
How CRISPR Can Be Used to Study GO:0010989 negative regulation of low-density lipoprotein particle clearance
Knockout
CRISPR knockout of PCSK9 or other candidate genes in hepatocyte models increases LDLR availability and LDL uptake, confirming their negative regulatory role.
Point Mutation
Introducing patient-derived point mutations into PCSK9 or LDLR allows functional assessment of variants associated with altered LDL clearance and cardiovascular risk.
Knock-in
Knock-in of tagged or variant alleles enables tracking of LDLR trafficking and degradation in response to PCSK9 or other regulators.
Overexpression
Overexpression of PCSK9 or other negative regulators reduces LDLR levels and LDL clearance, providing a gain-of-function complement to knockout studies.
How EDITGENE Supports negative regulation of low-density lipoprotein particle clearance Research
Researchers studying negative regulation of low-density lipoprotein particle clearance-related genes often need to determine whether a candidate gene is causally involved in reducing LDL uptake or whether its association is correlative. EDITGENE provides validated CRISPR models and screening services to answer these questions.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of low-density lipoprotein particle clearance research.
Frequently Asked Questions About negative regulation of low-density lipoprotein particle clearance
What is GO:0010989?
GO:0010989 is the Gene Ontology term for negative regulation of low-density lipoprotein particle clearance, describing any process that decreases the rate, frequency or extent of LDL removal from the blood via receptor-mediated endocytosis and degradation.
What genes are involved in negative regulation of LDL clearance?
Key genes include PCSK9, LDLR, APOB, APOA1, SURF4, LPA, SORT1, MTTP, ANGPTL3, APOC3, IDOL/MYLIP, HNF1A, SREBF2, NPC1L1, ABCG5, ABCG8 and CETP.
How does PCSK9 negatively regulate LDL clearance?
PCSK9 binds the LDL receptor and promotes its lysosomal degradation, reducing the number of receptors available to clear LDL from the blood.
Why is negative regulation of LDL clearance important for heart disease?
Because reduced LDL clearance raises plasma LDL-cholesterol, a causal risk factor for atherosclerosis and cardiovascular disease.
What experimental models are used to study LDL clearance regulation?
CRISPR knockout, point-mutation, knock-in and overexpression cell models, as well as genome-scale CRISPR screens and animal models, are commonly used.
Can CRISPR screens identify new regulators of LDL clearance?
Yes, genome-scale CRISPR screening has been used to interrogate cellular Lp(a) uptake and can identify genes involved in lipoprotein clearance pathways.
What is the role of SURF4 in cholesterol regulation?
Hepatic inactivation of SURF4 in mice results in a marked reduction in plasma cholesterol, implicating it in lipoprotein trafficking.
Do dietary fats affect LDL clearance?
Trans fatty acids have been evaluated for their mode of action in raising LDL cholesterol, with effects potentially involving altered LDL clearance pathways.
What diseases are linked to impaired LDL clearance?
Familial hypercholesterolemia, atherosclerosis, dyslipidemia and cardiovascular disease are linked to impaired LDL clearance.
How can I model PCSK9 variants with CRISPR?
Point-mutation knock-in can introduce specific PCSK9 variants into cell lines to study their effect on LDLR degradation and LDL uptake.
Conclusion
GO:0010989, negative regulation of low-density lipoprotein particle clearance, is a critical biological process that controls plasma LDL-cholesterol and cardiovascular risk. PCSK9 is the best-characterized negative regulator, but additional genes such as SURF4 and LPA-related pathways are emerging. CRISPR-based functional genomics provides a powerful approach to discover and validate new regulators, offering opportunities for therapeutic development.
References
- 1. Reichard JF et al.. 2016. Mode-of-action evaluation for the effect of trans fatty acids on low-density lipoprotein cholesterol.. Food Chem Toxicol 98(Pt B):282-294 PMID: 27241029
- 2. Lagace TA. 2014. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.. Curr Opin Lipidol 25(5):387-93 PMID: 25110901
- 3. Grejtakova D et al.. 2025. PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.. Cardiovasc Drugs Ther 39(6):1439-1451 PMID: 38907775
- 4. Braschi S et al.. 1999. Apolipoprotein A-I charge and conformation regulate the clearance of reconstituted high density lipoprotein in vivo.. J Lipid Res 40(3):522-32 PMID: 10064741
- 5. Tang VT et al.. 2022. Hepatic inactivation of murine Surf4 results in marked reduction in plasma cholesterol.. Elife 11 PMID: 36193893
- 6. Ke J et al.. 2022. Exploring the Genetic Association between Obesity and Serum Lipid Levels Using Bivariate Methods.. Twin Res Hum Genet 25(6):234-244 PMID: 36606461
- 8. Khan TG et al.. 2024. Functional interrogation of cellular Lp(a) uptake by genome-scale CRISPR screening.. bioRxiv PMID: 38766193
